WeTrials
Completed

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus

What is this study?

This study tests if an investigational medicine called survodutide helps adults with overweight or obesity and type 2 diabetes lose weight. It aims to see how well the medicine works compared to an inactive placeholder.

Who can participate?

You might be able to join if you are 18 or older, have a body mass index of 27 or higher, and have type 2 diabetes. Participants should also have struggled with weight loss through diet changes alone.

What will happen?

You will take either the study medicine or a placebo by giving yourself a weekly injection under the skin for about one and a half years. Everyone in the study also receives helpful counseling on healthy diet and exercise, along with regular check-ins with the study team.

Where and when?

This study has locations in the United States, including Alabama, Arizona, and California. The study status is currently completed.

Key Points
  • 1Tests the weight-loss medicine survodutide against a placebo
  • 2Involves weekly injections and lifestyle counseling for about 19 months
  • 3Open to adults with overweight or obesity and type 2 diabetes

Related video

HCPLive: SYNCHRONIZE-2 coordinating investigator Sean Wharton discusses the results (October 2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
ObesityDiabetes Mellitus, Type 2

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.